Eoin P. O’sullivan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eoin P. O’sullivan has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ann Wendy Morgan
School of Medicine, University of Leeds, Leeds, UK
2 shared publications - Charikleia Chatzigeorgiou
School of Medicine, University of Leeds , Leeds, UK
2 shared publications - Faye Elliott
Division of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom
2 shared publications - Jennifer H. Barrett
Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
2 shared publications - John C. Taylor
Pathology and Data Analytics, Leeds Institute for Medical Research at St James's, University of Leeds, UK; Leeds Institute for Data Analytics, University of Leeds, UK
2 shared publications - Sarah Louise Mackie
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
2 shared publications
Latest Publications
- 14 January 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (1) , e210137
Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder
Disease-related disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) is solely attributed to clinical attacks. However, few studies have assessed the relationship between attacks and residual disability in NMOSD. Thus, we aimed to quantify the contribution of clinical attacks to the residual disability in patients with AQP4-NMOSD. This retrospective observational single-center study enrolled patients from the Oxford National NMO Service, with the inclusion criteria as (1) AQP4-NMOSD diagnosis and (2) availability of at least 1 disability score (Expanded Disability Status Scale [EDSS] or logarithm of the minimum angle of resolution [LogMAR] score) recorded ≥6 months after attack (defined as residual disability). The outcome measures were EDSS and LogMAR scores. Univariable and multivariable linear mixed-effect models were used to quantify the effect of clinical relapses on the outcomes. A total of 165 patients with AQP4-NMOSD (median onset age, 43 years, range 2-84; women, 140 [84.8%]; White European patients, 92 [55.8%]; African or African British patients, 40 [24.2%]; Asian or Asian British patients, 20 [12.1%]; multiracial or unknown racial patients, 13 [7.9%]) were included, with the median time of disability measurement since the last attack being 32 months (range 6-197). The mean increase in the EDSS score per relapse was 0.304 (95% CI 0.074-0.553, p < 0.001), with individual relapse phenotypes showing different effects: the transverse myelitis (TM) + optic neuritis (ON) phenotype contributed most, with an increase of 1.290 (95% CI 0.233-2.207, p = 0.017) per relapse, followed by brain plus other phenotypes (β = 0.782, 95% CI 0.029-1.03, p < 0.001) and isolated TM (β = 0.295, 95% CI 0.074-0.549, p < 0.001), while neither brain nor optic nerve relapse alone was associated with a residual change in the EDSS score. Older onset age was correlated with more severe motor disability where this mainly occurred early in the disease course while younger patients exhibited mild initial disability that worsened more significantly with relapses. Each ON attack led to a mean increase of 0.464 (95% CI 0.199-0.741, p < 0.001) in the LogMAR score. Race, sex, and timing of acute treatment did not significantly affect these disability outcomes (EDSS and LogMAR scores). The quantitative contribution of relapse to the residual disability in patients with AQP4-NMOSD varies across phenotypes, and this relapse-related disability progression may also vary by the onset age. Although this retrospective single-center study may need validation in other data sets, these findings may help predict disability and provide a modeling tool for longer term disability in the cost-effective analysis of newer interventions.
- 14 January 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (1) , e210137
Quantitative Contribution of Clinical Attacks to Residual Disability in Patients With AQP4-Antibody Neuromyelitis Optica Spectrum Disorder
Disease-related disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) is solely attributed to clinical attacks. However, few studies have assessed the relationship between attacks and residual disability in NMOSD. Thus, we aimed to quantify the contribution of clinical attacks to the residual disability in patients with AQP4-NMOSD. This retrospective observational single-center study enrolled patients from the Oxford National NMO Service, with the inclusion criteria as (1) AQP4-NMOSD diagnosis and (2) availability of at least 1 disability score (Expanded Disability Status Scale [EDSS] or logarithm of the minimum angle of resolution [LogMAR] score) recorded ≥6 months after attack (defined as residual disability). The outcome measures were EDSS and LogMAR scores. Univariable and multivariable linear mixed-effect models were used to quantify the effect of clinical relapses on the outcomes. A total of 165 patients with AQP4-NMOSD (median onset age, 43 years, range 2-84; women, 140 [84.8%]; White European patients, 92 [55.8%]; African or African British patients, 40 [24.2%]; Asian or Asian British patients, 20 [12.1%]; multiracial or unknown racial patients, 13 [7.9%]) were included, with the median time of disability measurement since the last attack being 32 months (range 6-197). The mean increase in the EDSS score per relapse was 0.304 (95% CI 0.074-0.553, p < 0.001), with individual relapse phenotypes showing different effects: the transverse myelitis (TM) + optic neuritis (ON) phenotype contributed most, with an increase of 1.290 (95% CI 0.233-2.207, p = 0.017) per relapse, followed by brain plus other phenotypes (β = 0.782, 95% CI 0.029-1.03, p < 0.001) and isolated TM (β = 0.295, 95% CI 0.074-0.549, p < 0.001), while neither brain nor optic nerve relapse alone was associated with a residual change in the EDSS score. Older onset age was correlated with more severe motor disability where this mainly occurred early in the disease course while younger patients exhibited mild initial disability that worsened more significantly with relapses. Each ON attack led to a mean increase of 0.464 (95% CI 0.199-0.741, p < 0.001) in the LogMAR score. Race, sex, and timing of acute treatment did not significantly affect these disability outcomes (EDSS and LogMAR scores). The quantitative contribution of relapse to the residual disability in patients with AQP4-NMOSD varies across phenotypes, and this relapse-related disability progression may also vary by the onset age. Although this retrospective single-center study may need validation in other data sets, these findings may help predict disability and provide a modeling tool for longer term disability in the cost-effective analysis of newer interventions.
- Open Access
Common comorbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank
Objective To determine prevalent comorbidities in cases with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA) compared to matched controls. Methods Nested, cross sectional case-control study within UK Biobank. Case status was defined as self-reported prior diagnosis of PMR or GCA. 10 controls per case were matched for age, sex, ethnicity and assessment centre. Associations with selected self-reported comorbidities were studied using conditional logistic regression. Results Of PMR (n=1036) or GCA (n=102) cases, 72% were female, 98% white and 58% reported current use of glucocorticoids. Mean age was 63. At the time of the assessment visit, compared to controls, PMR/GCA cases were more likely to report poor general health and at least several days of low mood in the two past weeks. PMR was associated with hypothyroidism (odds ratio (OR) 1.34, 95% confidence interval (CI) 1.07-1.67) and ever-use of hormone replacement therapy (OR 1.26, CI 1.07-1.47). Regarding common comorbidities, PMR and GCA were both associated with hypertension (PMR: OR 1.21, CI 1.06-1.39; GCA: OR 1.86, CI 1.23-2.81) and cataract (PMR: OR 1.51, CI 1.19-1.93; GCA: OR 3.84, CI 2.23-6.60). Additionally GCA was associated with depression (OR 3.05, CI 1.59-5.85). Neither were associated with diabetes. Conclusion Participants with a history of PMR/GCA, including those not currently taking glucocorticoids, rated their health as poorer than matched controls,. Some previously-described disease associations (hypothyroidism and early menopause) were replicated. Hypertension and cataract, which can both be exacerbated by long-term glucocorticoid therapy, were over-represented in both diseases, particularly GCA. Key messages Comorbidity was common in individuals with self-reported prior diagnosis of PMR/GCA. PMR/GCA were associated with poorer self-reported health than controls; GCA was associated with depression. Hypertension and cataract were over-represented in PMR/GCA compared with controls but diabetes was not.
Open AccessCommon comorbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank
Objective To determine prevalent comorbidities in cases with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA) compared to matched controls. Methods Nested, cross sectional case-control study within UK Biobank. Case status was defined as self-reported prior diagnosis of PMR or GCA. 10 controls per case were matched for age, sex, ethnicity and assessment centre. Associations with selected self-reported comorbidities were studied using conditional logistic regression. Results Of PMR (n=1036) or GCA (n=102) cases, 72% were female, 98% white and 58% reported current use of glucocorticoids. Mean age was 63. At the time of the assessment visit, compared to controls, PMR/GCA cases were more likely to report poor general health and at least several days of low mood in the two past weeks. PMR was associated with hypothyroidism (odds ratio (OR) 1.34, 95% confidence interval (CI) 1.07-1.67) and ever-use of hormone replacement therapy (OR 1.26, CI 1.07-1.47). Regarding common comorbidities, PMR and GCA were both associated with hypertension (PMR: OR 1.21, CI 1.06-1.39; GCA: OR 1.86, CI 1.23-2.81) and cataract (PMR: OR 1.51, CI 1.19-1.93; GCA: OR 3.84, CI 2.23-6.60). Additionally GCA was associated with depression (OR 3.05, CI 1.59-5.85). Neither were associated with diabetes. Conclusion Participants with a history of PMR/GCA, including those not currently taking glucocorticoids, rated their health as poorer than matched controls,. Some previously-described disease associations (hypothyroidism and early menopause) were replicated. Hypertension and cataract, which can both be exacerbated by long-term glucocorticoid therapy, were over-represented in both diseases, particularly GCA. Key messages Comorbidity was common in individuals with self-reported prior diagnosis of PMR/GCA. PMR/GCA were associated with poorer self-reported health than controls; GCA was associated with depression. Hypertension and cataract were over-represented in PMR/GCA compared with controls but diabetes was not.
- Open Access
- 1 January 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 7 (3) , rkad095
Common co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank
Objective: The aim was to determine prevalent co-morbidities in cases with PMR or GCA compared with matched controls. Methods: This was a nested, cross-sectional case–control study within the UK Biobank, which recruited participants aged 40–69 years. Case status was defined as self-reported prior diagnosis of PMR or GCA. Ten controls per case were matched for age, sex, ethnicity and assessment centre. Associations with selected self-reported co-morbidities were studied using conditional logistic regression. Results: Of PMR (n = 1036) or GCA (n = 102) cases, 72% were female, 98% White, and 58% reported current use of glucocorticoids. Mean age was 63 years. At the time of the assessment visit, compared with controls, PMR/GCA cases were more likely to report poor general health and at least several days of low mood in the past 2 weeks. PMR was associated with hypothyroidism [odds ratio (OR) = 1.34; 95% CI = 1.07, 1.67] and ever-use of HRT (OR = 1.26; 95% CI = 1.07, 1.47). Regarding common co-morbidities, PMR and GCA were both associated with hypertension (PMR: OR = 1.21; 95% CI = 1.06, 1.39; GCA: OR = 1.86; 95% CI = 1.23, 2.81) and cataract (PMR: OR = 1.51; 95% CI = 1.19, 1.93; GCA: OR = 3.84; 95% CI = 2.23, 6.60). Additionally, GCA was associated with depression (OR = 3.05; 95% CI = 1.59, 5.85). Neither condition was associated with diabetes. Conclusion: Participants with a history of PMR/GCA, including those not currently taking glucocorticoids, rated their health as poorer than matched controls. Some previously described disease associations (hypothyroidism and early menopause) were replicated. Hypertension and cataract, both of which can be exacerbated by long-term glucocorticoid therapy, were over-represented in both diseases, particularly GCA.
- 1 January 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 7 (3) , rkad095
Open AccessCommon co-morbidities in polymyalgia rheumatica and giant cell arteritis: cross-sectional study in UK Biobank
Objective: The aim was to determine prevalent co-morbidities in cases with PMR or GCA compared with matched controls. Methods: This was a nested, cross-sectional case–control study within the UK Biobank, which recruited participants aged 40–69 years. Case status was defined as self-reported prior diagnosis of PMR or GCA. Ten controls per case were matched for age, sex, ethnicity and assessment centre. Associations with selected self-reported co-morbidities were studied using conditional logistic regression. Results: Of PMR (n = 1036) or GCA (n = 102) cases, 72% were female, 98% White, and 58% reported current use of glucocorticoids. Mean age was 63 years. At the time of the assessment visit, compared with controls, PMR/GCA cases were more likely to report poor general health and at least several days of low mood in the past 2 weeks. PMR was associated with hypothyroidism [odds ratio (OR) = 1.34; 95% CI = 1.07, 1.67] and ever-use of HRT (OR = 1.26; 95% CI = 1.07, 1.47). Regarding common co-morbidities, PMR and GCA were both associated with hypertension (PMR: OR = 1.21; 95% CI = 1.06, 1.39; GCA: OR = 1.86; 95% CI = 1.23, 2.81) and cataract (PMR: OR = 1.51; 95% CI = 1.19, 1.93; GCA: OR = 3.84; 95% CI = 2.23, 6.60). Additionally, GCA was associated with depression (OR = 3.05; 95% CI = 1.59, 5.85). Neither condition was associated with diabetes. Conclusion: Participants with a history of PMR/GCA, including those not currently taking glucocorticoids, rated their health as poorer than matched controls. Some previously described disease associations (hypothyroidism and early menopause) were replicated. Hypertension and cataract, both of which can be exacerbated by long-term glucocorticoid therapy, were over-represented in both diseases, particularly GCA.